{"id":"W2155012968","doi":"10.1200/jco.2008.16.9847","title":"Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":908,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Internal medicine; Renal cell carcinoma; Clinical endpoint; Hazard ratio; Gastroenterology; Proteinuria; Oncology; Surgery; Randomized controlled trial; Chemotherapy; Confidence interval; Kidney","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002443662,0.0006744482,0.00264817,0.0003763046,0.0003578893,0.0007786211,0.0006373534,0.0008808518,0.002416384],"category_scores_gemma":[0.00289114,0.0004273332,0.001800217,0.0005311111,0.0004811411,0.0004013324,0.0004566677,0.001844264,0.0003378572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001860825,"about_ca_system_score_gemma":0.002136664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009755515,"about_ca_topic_score_gemma":0.01989873,"domain_scores_codex":[0.999041,0.0005703272,0.00005646126,0.0001217117,0.0001232579,0.00008714919],"domain_scores_gemma":[0.9989682,0.0002579297,0.0003363203,0.00004527504,0.00007337253,0.000318855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9184204,0.004132637,0.009165103,0.000692402,0.003179527,0.00006879352,0.0001046564,0.001670444,0.002504624,0.0000908803,0.003589493,0.05638093],"study_design_scores_gemma":[0.8229398,0.1134048,0.04971293,0.0002656664,0.005669423,0.0002046755,0.00007663694,0.003903236,0.0007635197,0.0001899822,0.002822121,0.00004727692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876119,0.007836751,0.0001767191,0.001555562,0.0002760443,0.0005100945,0.0005037098,0.00006345556,0.001465714],"genre_scores_gemma":[0.9913265,0.003596921,0.0007408162,0.001528527,0.0002659802,0.0004695219,0.001153535,0.00001080356,0.0009073316],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009755515,"threshold_uncertainty_score":0.0193975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0995623420053774,"score_gpt":0.3685206473544246,"score_spread":0.2689583053490472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}